{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"100","value":"80"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"University of Washington Quality of Life (UW-QOLR) questionnaire - covers 12 domains - pain, appearance, activity, recreation, swallowing, chewing, speech, shoulder function, taste, saliva, mood and anxiety. Each domain have between 3 and 6 response options that are scaled evenly from 0 (worst) to 100 (best) according to the hierarchy of response and reported as one composite score from 0 (worst) to 100 (best).","dispersionType":"Full Range","groups":[{"description":"Cetuximab - 250 mg/m2 on Day 1 after the first dose of radiation was administered to all patients. Hydroxyurea - 500 mg orally every 12 hours with the morning dose administered 2 hours before radiation. Fluorouracil - continuous-infusion 5-FU at a dose of 600 mg/m2 daily for 120 hours. Radiotherapy.","id":"OG000","title":"Advanced Head and Neck Cancer"}],"paramType":"MEAN","populationDescription":"Twenty patients completed the UW-QOLR questionnaire before and after therapy.","reportingStatus":"POSTED","timeFrame":"2 years","title":"UW-QOLR: Quality of Life Score","type":"SECONDARY","unitOfMeasure":"units on a scale"}